867 related articles for article (PubMed ID: 16634964)
21. Peripheral blood picture in primary hypocellular refractory anemia and idiopathic acquired aplastic anemia: an additional tool for differential diagnosis.
Elghetany MT; Hudnall SD; Gardner FH
Haematologica; 1997; 82(1):21-4. PubMed ID: 9107077
[TBL] [Abstract][Full Text] [Related]
22. Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes.
Lundberg LG; Hellström-Lindberg E; Kanter-Lewensohn L; Lerner R; Palmblad J
Leuk Res; 2006 Mar; 30(3):247-53. PubMed ID: 16099505
[TBL] [Abstract][Full Text] [Related]
23. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
24. [Clinical significance of WHO classification and MDS 2000 classification in myelodysplastic syndromes].
Akiba M; Matsuda A; Misumi M; Yagasaki F; Bessho M
Rinsho Ketsueki; 2001 Dec; 42(12):1162-9. PubMed ID: 11828718
[TBL] [Abstract][Full Text] [Related]
25. Refractory anemia and the myelodysplastic syndromes.
Lawrence LW
Clin Lab Sci; 2004; 17(3):178-86. PubMed ID: 15314893
[TBL] [Abstract][Full Text] [Related]
26. Hypoplastic myelodysplastic syndrome (h-MDS) is a distinctive clinical entity with poorer prognosis and frequent karyotypic and FISH abnormalities compared to aplastic anemia (AA).
Koh Y; Lee HR; Song EY; Kim HK; Kim I; Park S; Park MH; Kim BK; Yoon SS; Lee DS
Leuk Res; 2010 Oct; 34(10):1344-50. PubMed ID: 20427085
[TBL] [Abstract][Full Text] [Related]
27. p53 expression in myeloid cells of myelodysplastic syndromes. Association with evolution of overt leukemia.
Kitagawa M; Yoshida S; Kuwata T; Tanizawa T; Kamiyama R
Am J Pathol; 1994 Aug; 145(2):338-44. PubMed ID: 8053492
[TBL] [Abstract][Full Text] [Related]
28. Characterization of myelodysplastic syndrome and aplastic anemia by immunostaining of p53 and hemoglobin F and karyotype analysis: differential diagnosis between refractory anemia and aplastic anemia.
Iwasaki T; Murakami M; Sugisaki C; Sobue S; Ohashi H; Asano H; Suzuki M; Nakamura S; Ito M; Murate T
Pathol Int; 2008 Jun; 58(6):353-60. PubMed ID: 18477214
[TBL] [Abstract][Full Text] [Related]
29. Cytogenetic characteristics of patients with signs and symptoms of myelodysplastic syndromes in the State of Pará, Brazil.
Pinto GR; Overal DJ; Moraes LS; Van Den Berg AV; Lemos JA; Smith Mde A; Burbano RR
Genet Mol Res; 2005 Mar; 4(1):18-30. PubMed ID: 15841432
[TBL] [Abstract][Full Text] [Related]
30. In vitro growth modulation by L-ascorbic acid of colony-forming cells from bone marrow of patients with myelodysplastic syndromes.
Park CH; Kimler BF; Bodensteiner D; Lynch SR; Hassanein RS
Cancer Res; 1992 Aug; 52(16):4458-66. PubMed ID: 1643638
[TBL] [Abstract][Full Text] [Related]
31. Circulating myeloid colony-forming cells predict survival in myelodysplastic syndromes.
Berer A; Jäger E; Sagaster V; Streubel B; Wimazal F; Sperr WR; Welterman A; Schwarzinger I; Frommlet F; Haas OA; Valent P; Lechner K; Geissler K; Ohler L
Ann Hematol; 2003 May; 82(5):271-7. PubMed ID: 12739063
[TBL] [Abstract][Full Text] [Related]
32. [Relationship between the occurrences of AL, MDS and AA and abnormal BM proliferation of patient's parents].
Feng BZ; Lei JL; Lin ZX; Shao ZH; Wang Q
Yi Chuan Xue Bao; 1998 Apr; 25(2):103-11. PubMed ID: 9752008
[TBL] [Abstract][Full Text] [Related]
33. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.
Malcovati L; Porta MG; Pascutto C; Invernizzi R; Boni M; Travaglino E; Passamonti F; Arcaini L; Maffioli M; Bernasconi P; Lazzarino M; Cazzola M
J Clin Oncol; 2005 Oct; 23(30):7594-603. PubMed ID: 16186598
[TBL] [Abstract][Full Text] [Related]
34. Immunophenotype of myeloid cells in myelodysplastic syndromes and its clinical implications.
Shao Z; Chen G; Lin Z; Zhang Y; Hao Y; Chu Y; Zheng Y; Qian L; Yang T; Yang C; Feng B
Chin Med J (Engl); 1998 Jan; 111(1):28-31. PubMed ID: 10322648
[TBL] [Abstract][Full Text] [Related]
35. [Study on the immunophenotype of myeloid cells in myelodysplastic syndromes and its clinical implications].
Shao Z; Chen G; Lin Z; Zhang Y; Hao Y; Chu Y; Qian L; Yang T; Yang C; Feng B
Zhonghua Xue Ye Xue Za Zhi; 1997 Feb; 18(2):80-3. PubMed ID: 15622783
[TBL] [Abstract][Full Text] [Related]
36. Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category.
Bacher U; Schnittger S; Kern W; Weiss T; Haferlach T; Haferlach C
Ann Hematol; 2009 Dec; 88(12):1207-13. PubMed ID: 19415278
[TBL] [Abstract][Full Text] [Related]
37. Essential thrombocythemia with ringed sideroblasts: a heterogeneous spectrum of diseases, but not a distinct entity.
Schmitt-Graeff A; Thiele J; Zuk I; Kvasnicka HM
Haematologica; 2002 Apr; 87(4):392-9. PubMed ID: 11940483
[TBL] [Abstract][Full Text] [Related]
38. [Evolutive epidemiologic profile of myelodysplastic syndromes (1959-1993). Comparative study with acute myeloid leukemia and aplastic pancytopenias].
Sánchez Fayos J; Outeiriño Pérez JJ; Prieto E; Román A; Olavarría E; Cabello A; Soto C; Calabuig T; Paniagua C; Sanz B
Sangre (Barc); 1994 Dec; 39(6):441-8. PubMed ID: 7855696
[TBL] [Abstract][Full Text] [Related]
39. [Karyotypic and IPSS grouping of primary myelodysplastic syndromes patients: a comparison between FAB- and WHO-classification].
Yu MH; Liu SH; Shao YQ; Hao YS; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2004 Aug; 25(8):482-5. PubMed ID: 15555265
[TBL] [Abstract][Full Text] [Related]
40. Outcome of patients with myelodysplastic syndromes: experience from a single institution in South Australia.
Hui CH; Horvath N; Lewis I; To LB; Szabo F
Intern Med J; 2008 Nov; 38(11):824-8. PubMed ID: 18284457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
